Important developments on the GI cancer front to watch out for
A rock around the myeloma clock through the eyes of a KOL - what stood out and what did not?
Beyond CAR-T cell therapy there are novel bispecifics coming along so where and how will they fit in?
A critical look at the early stage BMS oncology pipeline
Commentary on engineered NK cells, including CAR-NK and memory-like NK cells
Expert commentary on new data relating to NK cell therapies - are they ready for prime time yet or not?
What caught our attention on novel bispecific antibodies at ASH20?
Updated look at the bispecific landscape in early clinical development
How we can learn more from failure in clinical trials so we can improve outcomes further with emerging agents in early development
Winners, losers and risers... who goes where in the final analysis?
What to watch out for this weekend in targeted therapies and early stage new product development
Five IO areas in early stage development to watch out for at ESMO20
Can we predict the future cancer drug combinations from emerging new targets?
If we were to tackle CAR T cell therapy design differently, how would we go about doing it?
The ups and downs of CAR-T cell therapy development continues apace
Update on the Gamma Delta T cell niche - what's new, what's up, and what's down?
A look at some novel and promising approaches in early oncology new product development
An update on the CD20 x CD3 bispecific with expert commentary on data at ASCO EHA.
Ten intriguing novel agents in early development to watch out for
When T cells stop working how can we get innate immune cells like NK cells to take up the slack and help track down tumours?
A look at what happened from the DREAMM1 to DREAMM2 trials exploring the BCMA ADC belantamab mafadotin in refractory multiple myeloma and why GSK have a challenge ahead
A look at some of the highly ranked clinical data presented over the weekend in Orlando
Some hidden gems and under the radar abstracts that may appeal to the off-Broadway crowd at ASH19
If we want to improve on the current results with IO therapies then we need to go to basics and understand the biology of each disease subset in the context of what we've learned so far
What did we learn at #Targets19 about targeting NRG1 gene fusions with MCLA-128?
Thoughts and commentary on the Jounce-Celgene collaboration update and the emerging ICOS landscape
Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?
What can we learn from the recent data presented on Affimed's innate bispecific platform? A candid conversation with CEO, Dr Adi Hoess
We saw a number of challenges emerge with immune agonists as antibodies and now companies are experimenting with them in bispecifics - what needs to be considered to make them work? What will the next wave of IO look like?
How the design of different cancer approaches can affect clinical performance
Round-up and analysis of key lymphoma data at iCML 2019
Highlights (and lowlights) from Day 2 of immunotherapy presentations at CIMT 2019 in Mainz.
A review of 7 different targets and 18 different compounds in the maturing and highly competitive bispecific niche.
Is there a better way to target myeloma than with BCMA alone? Data suggests there's plenty of room for improvement.
Update on T cell bispecifics and other key topics in early stage IO development
An upcoming small biotech focused on IO targets with their novel platform approach
Some examples of potentially useful biomarker inclusion in early oncology trials
What to watch out for at the ASCO GI19 conference in San Francisco
Going beyond anti-PD1 checkpoint blockade is important if we want to help more people respond to cancer immunotherapy
FDA slaps a partial clinical hold for unwanted side effects, now what?
Review of a round dozen key abstracts at #ASH18, both scientific and clinical data is under the microscope!
We offer 13 key highlights from day 2 of ASH18, including some surprises.
From one BCMA directed CAR in 2015, we now have a very competitive niche in multiple myeloma. What's in store?
An extensive round-up of what to expect from SITC18 ahead of the abstract reveal
Lessons learned from recent failure and a look at where a few new developments might be coming from...
Part 1 of our #CICON18 Previews - a look at 11 intriguing IO related studies
Update on BCMA, SLAMF7 and other targets in multiple myeloma
Will NK cell engagers have a positive impact on checkpoint therapy and other adaptive immunotherapies?
Bringing together disparate notes on cytokines and how they can be useful as an immunotherapy partner.
How do we drive more T cells into the tumour? Here's one company who are looking to do just that.
A look at the pipeline of the up and coming Seattle biotech, Alpine Immune Sciences
A look at key pipeline developments in multiple myeloma through the lens of a global expert in the field
With increasing evidence that CD123 is a suboptimal target in AML, what other approaches might be more useful to consider?
A look at the Class of 2018 new products in development - a hit or miss?
Jumpstarting the immune system with a synthetic immunity approach - how can we do this?
How can we boost the efficacy of checkpoint therapies? One way is to drive more activated T cells into the tumour.
Overcoming resistance to monotherapy treatment with checkpoint blockade is crucial for success with IO combos. Here's one potential solution...
A look at an up and coming niche in cancer research that may turn out to be useful in conjunction with checkpoint blockade
With so many new anti-cancer agents, including immunotherapies, emerging in company pipelines, this means that we could see the evolution of important therapy sequences... going beyond combinations.
The oncology bispecific market is heating up with J&J collaborating with Macrogenics and Novartis with Xencor. We discuss the skinny...
In this post I've taken a close look at one cancer immunotherapy approach with a lot of data at AACR - bispecific T cell engagers.
A primer on immunocytokines in cancer immunotherapy with a focus on Roche's CEA-IL2v as a example.
The Mav's key oral abstracts to follow at #ASH17 -- warning this list includes quirky selections!
What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?